Search

Your search keyword '"Wingerchuk, Dean M."' showing total 789 results

Search Constraints

Start Over You searched for: Author "Wingerchuk, Dean M." Remove constraint Author: "Wingerchuk, Dean M."
789 results on '"Wingerchuk, Dean M."'

Search Results

53. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder

56. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder

57. Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders

58. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum

59. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies

63. sj-pdf-2-msj-10.1177_13524585211038291 – Supplemental material for Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

64. sj-docx-1-mso-10.1177_20552173211052656 - Supplemental material for Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders

65. sj-docx-1-msj-10.1177_13524585211038291 – Supplemental material for Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

66. sj-pdf-1-msj-10.1177_13524585211038291 – Supplemental material for Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

70. Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension

72. Transverse myelitis

80. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

87. CONTRIBUTING AUTHORS

89. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.

91. Effects of Age and Sex on Aquaporin-4 Autoimmunity

96. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide

97. Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study (1780)

98. Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study (1765)

99. Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder (1494)

100. Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study (1299)

Catalog

Books, media, physical & digital resources